Bristol-Myers Squibb Stock: Is BMY Outperforming the Healthcare Sector?

Bristol-Myers Squibb Stock: Is BMY Outperforming the Healthcare Sector?

Thu, September 3, 2026 at 6:39 PM GMT+3 2 min read

• BMY -1.87%
• XLV -1.04%

With a market cap of $138.2 billion, Bristol-Myers Squibb Company (BMY) is a global biopharmaceutical company that discovers, develops, manufactures, and markets innovative medicines worldwide. Its portfolio spans key therapeutic areas including oncology, hematology, immunology, cardiovascular disease, and neuroscience, with well-known products such as Opdivo, Eliquis, Revlimid, and Yervoy.

Companies valued at $10 billion or more are generally classified as "large-cap" stocks, and Bristol-Myers Squibb fits this criterion perfectly. The company serves patients through a broad commercial network that includes wholesalers, distributors, specialty pharmacies, hospitals, clinics, and government agencies.

More News from Barchart

Shares of the Princeton, New Jersey-based company have slipped 1.7% from its 52-week high of $68.64. The stock has soared 22.7% over the past three months, surpassing the State Street Health Care Select Sector SPDR ETF's (XLV) 16.4% gain over the same time frame.

BMY stock is up 24.5% on a YTD basis, outperforming XLV's 10.9% increase. Moreover, shares of the company have surged 41.4% over the past 52 weeks, compared to XLV's 25.4% return over the same time frame.

The stock has been trading above its 50-day and 200-day moving averages since November 2025.

Bristol Myers Squibb shares rose 2.8% on Jul. 30 as Q2 2026 revenue reached $12.97 billion and adjusted EPS of $2.04, both beat expectations. The company also raised its 2026 revenue forecast to $49 billion - $50 billion and adjusted EPS guidance to $6.75 - $7, with Eliquis sales rising 22% to $4.48 billion and its full-year growth forecast lifted to 20% - 25%. Strong demand for newer medicines further supported the outlook, with Reblozyl, Camzyos and Breyanzi all beating sales expectations, while the growth portfolio expanded 15% despite declines in older drugs such as Revlimid.

In contrast, rival Eli Lilly and Company (LLY) has lagged behind BMY stock on a YTD basis, with LLY shares up 7.2%. Nevertheless, LLY stock has soared 56.1% over the past 52 weeks, outperforming Bristol-Myers Squibb shares.

Despite BMY's outperformance relative to the sector, analysts remain cautiously optimistic about its prospects. The stock has a consensus rating of "Moderate Buy" from 30 analysts in coverage, and as of writing, the stock is trading above the mean price target of $66.48.

On the date of publication, Sohini Mondal did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Barchart.com